<DOC>
	<DOCNO>NCT02717364</DOCNO>
	<brief_summary>This study local , prospective , non-interventional , non-controlled , multicenter , observational study ( regulatory postmarketing surveillance ) . Each physician enroll patient receive least 1 dose Yervoy , patient follow 12 month . All patient evaluate safety effectiveness Yervoy use ( 4 dos ) 12 month first dose Yervoy confirm safety profile Yervoy routine , daily practice</brief_summary>
	<brief_title>YervoyÂ® Postmarketing Surveillance Patients Japan With Unresectable , Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>All patient initiate treatment Yervoy Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>